Mitsubishi UFJ Trust & Banking Corp Sells 2,478 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Mitsubishi UFJ Trust & Banking Corp trimmed its stake in Thermo Fisher by 1.1% in Q4, selling 2,478 shares and leaving it with 216,728 shares worth about $125.6 million (roughly 0.06% ownership).
• Thermo Fisher beat quarterly expectations with EPS of $5.44 vs. $5.25 and revenue of $11.01 billion vs. $10.86 billion, issued FY2026 EPS guidance of 24.640–25.120, and carries a MarketBeat consensus rating of "Buy" with an average target of $623.05.
• Insider activity and payout: CEO Marc N. Casper sold 5,000 shares for about $2.56 million (a 3.88% reduction in his stake), and the company increased its quarterly dividend to $0.47 (annualized $1.88, ~0.4% yield).

Mitsubishi UFJ Trust & Banking Corp lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 216,728 shares of the medical research company's stock after selling 2,478 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.06% of Thermo Fisher Scientific worth $125,583,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in TMO. JPL Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific during the third quarter valued at $28,000. Beacon Financial Strategies CORP bought a new position in Thermo Fisher Scientific in the 4th quarter worth about $29,000. Olistico Wealth LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Cloud Capital Management LLC bought a new stake in Thermo Fisher Scientific during the 3rd quarter valued at about $31,000. Finally, KERR FINANCIAL PLANNING Corp purchased a new position in Thermo Fisher Scientific in the third quarter worth about $38,000. 89.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the subject of several analyst reports. TD Cowen reduced their price target on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a research report on Friday, January 30th. Evercore reaffirmed an "outperform" rating and issued a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Morgan Stanley reissued an "overweight" rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday. Jefferies Financial Group raised Thermo Fisher Scientific to a "strong-buy" rating in a report on Friday. Finally, Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $623.05.

Thermo Fisher Scientific Trading Down 0.3%

Shares of TMO stock opened at $468.21 on Tuesday. The stock has a market capitalization of $174.00 billion, a P/E ratio of 25.74, a P/E/G ratio of 2.33 and a beta of 0.97. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The firm's 50 day moving average is $498.38 and its 200 day moving average is $549.15. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion for the quarter, compared to analysts' expectations of $10.86 billion. During the same period in the prior year, the firm earned $5.15 EPS. The company's revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 24.83 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were paid a dividend of $0.47 per share. The ex-dividend date was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's dividend payout ratio is presently 10.34%.

Insider Activity

In other news, CEO Marc N. Casper sold 5,000 shares of the company's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company's stock, valued at $63,499,170. This represents a 3.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the transaction, the executive vice president directly owned 20,752 shares in the company, valued at approximately $11,230,982.40. The trade was a 1.89% decrease in their position. The SEC filing for this sale provides additional information. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.